Advertisement

Topics

Seattle Genetics and Takeda Announce Positive Results from Late-Stage NHL Trial

11:12 EDT 29 Jun 2017 | Speciality Pharma Journal

CAMBRIDGE, Mass., OSAKA, Japan & BOTHELL, Wash.–(BUSINESS WIRE)–Jun. 26, 2017– Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (PFS) versus the control arm. ECHELON-1 is a randomized, multicenter trial evaluating …

Original Article: Seattle Genetics and Takeda Announce Positive Results from Late-Stage NHL Trial

NEXT ARTICLE

More From BioPortfolio on "Seattle Genetics and Takeda Announce Positive Results from Late-Stage NHL Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...